Biogen (NASDAQ:BIIB) Price Target Cut to $213.00 by Analysts at Royal Bank Of Canada

Biogen (NASDAQ:BIIB) had its target price lowered by stock analysts at Royal Bank Of Canada from $233.00 to $213.00 in a research note issued on Tuesday,MarketScreener reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 23.27% from the company’s current price.

Several other research firms also recently commented on BIIB. Canaccord Genuity Group boosted their target price on shares of Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Barclays initiated coverage on shares of Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price objective for the company. UBS Group initiated coverage on shares of Biogen in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price objective for the company. Finally, BMO Capital Markets upped their price objective on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Twelve investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $207.54.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $172.79 on Tuesday. Biogen has a twelve month low of $110.04 and a twelve month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $25.36 billion, a PE ratio of 19.47, a P/E/G ratio of 2.37 and a beta of 0.16. The firm has a fifty day simple moving average of $186.58 and a 200 day simple moving average of $171.93.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts forecast that Biogen will post 15.83 EPS for the current year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Reflection Asset Management purchased a new position in Biogen in the fourth quarter valued at about $25,000. WPG Advisers LLC boosted its stake in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the last quarter. Accredited Wealth Management LLC lifted its stake in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp purchased a new stake in shares of Biogen during the 4th quarter valued at approximately $30,000. Finally, WFA of San Diego LLC purchased a new stake in shares of Biogen during the 2nd quarter valued at approximately $32,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen announced a multi-target collaboration and license with Alloy Therapeutics to use Alloy’s AntiClastic™ antisense oligonucleotide (ASO) platform, giving Biogen access to RNA-targeting capabilities that can expand its early-stage pipeline and long-term growth optionality. Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
• Neutral Sentiment: RBC trimmed its price target on BIIB to $213 but kept an Outperform rating, signalling continued analyst confidence in the company’s prospects while slightly lowering near-term upside expectations. Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform
• Neutral Sentiment: Broader health-care sector softness weighed on sentiment, contributing to downward pressure across names including Biogen despite company-specific pipeline news. Sector Update: Health Care Stocks Softer Late Afternoon
• Negative Sentiment: Biogen disclosed that first‑quarter results will include an acquired in‑process R&D, upfront and milestone expense of $34M (pre‑tax), and commentary indicates Q1 expenses will be notably higher than previously expected — a near-term earnings headwind that prompted investor selling. Biogen Expects 1Q Results Will Include Acquired In-Process R&D, Upfront and Milestone Expense of $34M on Pre-Tax Basis
• Negative Sentiment: Deal activity tied to Biogen (reports about the company’s recent acquisitions/agreements) is boosting targets’ shares (e.g., Apellis) but signals near-term cash outlays and integration risk for Biogen, which investors are treating as a short-term negative for margins and free cash flow. Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here’s What Shareholders Get

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.